Organ-on-a-Chip Resources

How OOC can improve in vitro to in vivo translatability of preclinical data

PhysioMimix® DILI assay kit: Human 24 for deeper mechanistic hepatotoxicity insights

Confidently predict DILI with PhysioMimix DILI assay kit: Human 24-accurate, human-relevant mechanistic hepatotoxicity insights to enhance drug safety in development

Addressing the challenges of developing new modality drugs

Discover how new modality drugs are revolutionizing medicine by targeting complex diseases with cutting-edge therapies. Learn about the challenges, innovative solutions, and the role of AI and Organ-on-a-chip (OOC) technology in new modality drug development. Expert insights.

How Organ-on-a-chip can reduce DILI risk in drug development

Drug-induced Liver injury is a common cause of drug withdrawal during late drug development as well as post-approval. The liver, a primary site of drug metabolism, is particularly susceptible. However, DILI can occur through several pathways, each involving different mechanisms.

This article explores why traditional in vitro and in vivo animal studies are less able to predict more complex indirect or idiosyncratic effects that are latent in onset and how preclinical workflows can be modernized to reduce risk through Organ-on-a-chip’s mechanistic insights.

Evaluating a human DILI assay kit’s ability to unlock complex mechanisms of toxicity

Here, we demonstrate how the PhysioMimix DILI assay kit: Human 24 and PhysioMimix OOC Single-organ System captures more complex mechanisms of human DILI than traditional preclinical approaches to reduce the risk of unforeseen event detection in the clinic.

Go/No-Go

Webinar Series 7 Episode 3

In this webinar “Go/No-Go” we demonstrate how to further de-risk development workflows with the PhysioMimix^® DILI assay. Using drugs that were identified as toxic in the clinic, we reveal some of the data-rich investigative toxicology studies that can be achieved using a human liver microphysiological system (MPS), otherwise known as organ-on-a-chip (OOC).

Lost in Translation

Webinar Series 7 Episode 2

This MPS webinar explores how you can improve your clinical translation by applying microphysiological systems (MPS) / Organ-on-a-chip (OOC) to bridge the gap between preclinical research and clinical trials. Discover how MPS/OOC improve drug candidate assessment by generating physiologically relevant data, reduce DILI risks, and accelerate drug development.

Bridging the gap

Drug-induced liver injury (DILI) remains the most common cause for acute liver failure in the world and is a leading cause of compound attrition in drug discovery. Although sufficient at capturing most intrinsic events, current models used in drug discovery have limitations as they are not effective at predicting or understanding more complex DILI events in humans. Furthermore, for testing new human-specific modalities, cell lines/animal models are less suitable due to genetic or immunological response differences. Using the PhysioMimix® Organ-on-a-Chip (OOC) System, human and preclinical animal microphysiological system (MPS) models have been developed to bridge these gaps.

Organ-on-a-chip adoption: The roadmap to broader use

This blog explores challenges faced by the Pharmaceutical industry that pave the way for Organ-on-a-chip adoption and why it makes sense to start with toxicology workflows.

Developed the model, built the assay, now a focus on THROUGHPUT! The Liver-48, designed for industry adoption

The PhysioMimix® Liver-48 plate poster: CN Bio’s Multi-chip Liver-48 plate retains SBS-standard footprint, maintains Liver MPS functionality, and increasing throughput. By miniaturizing each chip, 48 tissues can be cultured per plate, 144 chips per PhysioMimix Single-organ HT System – more replicates and controls for fast, robust and cost-effective understanding of human drug safety earlier in the pipeline.

Understanding the mechanism of toxicity: OOC’s crucial role

It’s commonly acknowledged that the current drug discovery process is inefficient with large numbers of drugs failing in the clinic. Almost a third fail due to undetected toxicity issues. Countless more potential drugs fail due to misclassification by animal models.

Beyond hepatotoxicity red flags

Webinar Series 6 Episode 1

Standard preclinical approaches are poorly predictive, particularly for drugs eliciting human-specific toxicity or idiosynchratic DILI. In this webinar, Dr. Anthony Berger, a Field Application Scientist at CN Bio will discuss how liver-on-a-chip (LOAC) cocultures of primary hepatocytes offer a solution.